Trevi Therapeutics Schedules Investor Roadshow Ahead of Key Data Readouts
Event summary
- Trevi Therapeutics will participate in the Needham Virtual Healthcare Conference (April 13-16), the Raymond James Biotech Innovation Symposium (April 14), and Oppenheimer’s Innovation on the Island (April 27-29).
- The company will host an Investor and Analyst Day on May 7 in New York City, featuring key opinion leaders in chronic cough.
- Jennifer Good (CEO) and David Hastings (CFO) will represent Trevi at all listed events.
- Haduvio™ (nalbuphine ER) is the company’s investigational therapy targeting chronic cough in IPF, non-IPF ILD, and RCC.
The big picture
Trevi’s investor events coincide with a period of heightened scrutiny for companies targeting rare respiratory diseases. The company’s reliance on Haduvio to address a significant unmet need—affecting hundreds of thousands of patients—positions it for potential success, but also exposes it to considerable clinical and regulatory risk. The upcoming Investor and Analyst Day will be a key indicator of investor confidence and the perceived value of Trevi’s KAMA mechanism of action.
What we're watching
- Data Dependency
- The success of Trevi's investor roadshow and subsequent valuation will be heavily influenced by the reception of Haduvio's clinical trial data, particularly regarding efficacy and safety.
- Regulatory Risk
- While nalbuphine is not currently scheduled by the DEA, any future changes to regulatory status could significantly impact Haduvio's commercial viability and market access.
- Competition
- The lack of FDA-approved therapies for RCC and IPF-related cough creates a large market opportunity, but the emergence of competing therapies could erode Haduvio’s potential market share.
Related topics